The role of the MHC on resistance to group A streptococci in mice

Journal of Immunology

Volumn 175, Issue 6, 2005, Pages 3862-3872

  Goldmann, Oliver ^a   Lengeling, Andreas ^a   Böse, Jens ^a   Bloecker, Helmut ^a   Geffers, Robert ^a   Chhatwal, Gursharan S ^a   Medina, Eva ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHROMOSOME 17; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENETIC LINKAGE; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; HAPLOTYPE; INFECTION SENSITIVITY; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATOR GENE; SEPSIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

EID: 24744436389     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.6.3862     Document Type: Article

References (58)

1. Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13: 470-511.
2. Norrby-Teglund, A., R. Lustig, and M. Kotb. 1997. Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates. Infect. Immun. 65: 5209-5215.
3. Chatellier, S., N. Ihendyane, R. G. Kansal, F. Khambaty, H. Basma, A. Norrby-Teglund, D. E. Low, A. McGeer, and M. Kotb. 2000. Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 68: 3523-3534.
4. Kotb, M., A. Norrby-Teglund, A. McGeer, H. El-Sherbini, M. T. Dorak, A. Khurshid, K. Green, J. Peeples, J. Wade, G. Thomson, et al. 2002. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med. 8: 1398-1404.
5. Norrby-Teglund, A., S. Chatellier, D. E. Low, A. McGeer, K. Green, and M. Kotb. 2000. Host variation in cytokine responses to superantigens determines the severity of invasive group A streptococcal infection. Eur. J. Immunol. 30: 3247-3255.
6. Stevens, D. L., M. H. Tanner, J. Winship, R. Swarts, K. M. Ries, P. M. Schlievert, and E. Kaplan. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321: 1-7.
7. Musser, J. M., A. R. Hauser, M. H. Kim, P. M. Schlievert, K. Nelson, and R. K. Selander. 1991. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc. Natl. Acad. Sci. USA 88: 2668-2672.
8. Watanabe-Ohnishi, R., D. E. Low, A. McGeer, D. L. Stevens, P. M. Schlievert, D. Newton, B. Schwartz, B. Kreiswirth, and M. Kotb. 1995. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome: Ontario Streptococcal Study Project. J. Infect. Dis. 171: 74-84.
9. Weeks, C. R., and J. J. Ferretti. 1986. Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12. Infect. Immun. 52: 144-150.
10. Goshorn, S. C., G. A. Bohach, and P. M. Schlievert. 1988. Cloning and characterization of the gene, speC, for pyrogenic exotoxin type C from Streptococcus pyogenes. Mol. Gen. Genet. 212: 66-70.
11. Mollick, J. A., G. G. Miller, J. M. Musser, R. G. Cook, D. Grossman, and R. R. Rich. 1993. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J. Clin. Invest. 92: 710-719.
12. Proft, T., S. L. Moffatt, C. J. Berkahn, and J. D. Fraser. 1999. Identification and characterization of novel superantigens from Streptococcus pyogenes. J. Exp. Med. 189: 89-102.
13. Proft, T., P. D. Webb, V. Handley, and J. D. Fraser. 2003. Two novel superantigens found in both group A and group C Streptococcus. Infect. Immun. 71: 1361-1369.
14. Verhoef, J., and E. Mattsson. 1995. The role of cytokines in Gram-positive bacterial shock. Trends Microbiol. 3: 136-140.
15. Dinarello, C. A. 1996. Cytokines as mediators in the pathogenesis of septic shock. Curr. Top. Microbiol. Immunol. 216: 133-165.
16. McCormick, J. K., J. M. Yarwood, and P. M. Schlievert. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55: 77-104.
17. Sriskandan, S., D. Moyes, and J. Cohen. 1996. Detection of circulating bacterial superantigen and lymphotoxin-α in patients with streptococcal toxic-shock syndrome. Lancet 348: 1315-1316.
18. Norrby-Teglund, A., P. Thulin, B. S. Gan, M. Kotb, A. McGeer, J. Andersson, and D. E. Low. 2001. Evidence for superantigen involvement in severe group a streptococcal tissue infections. J. Infect. Dis. 184: 853-860.
19. Llewelyn, M., S. Sriskandan, M. Peakman, D. R. Ambrozak, D. C. Douek, W. W. Kwok, J. Cohen, and D. M. Altmann. 2004. HLA class II polymorphisms determine responses to bacterial superantigens. J. Immunol. 172: 1719-1726.
20. Norrby-Teglund, A., G. T. Nepom, and M. Kotb. 2002. Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles. Eur. J. Immunol. 32: 2570-2577.
21. Medina, E., O. Goldmann, M. Rohde, A. Lengeling, G. S. Chhatwal, and G. S. Chhatwals. 2001. Genetic control of susceptibility to group A streptococcal infection in mice. J. Infect. Dis. 184: 846-852.
22. Goldmann, O., G. S. Chhatwal, and E. Medina. 2003. Immune mechanisms underlying host susceptibility to infection with group A streptococci. J. Infect. Dis. 187: 854-861.
23. Witmer, P. D., K. F. Doheny, M. K. Adams, C. D. Boehm, J. S. Dizon, J. L. Goldstein, T. M. Templeton, A. M. Wheaton, P. N. Dong, E. W. Pugh, et al. 2003. The development of a highly informative mouse simple sequence length polymorphism (SSLP) marker set and construction of a mouse family tree using parsimony analysis. Genome Res. 13: 485-491.
24. Manly, K. F., R. H. Cudmore, Jr., and J. M. Meer. 2001. Map Manager QTX, cross-platform software for genetic mapping. Mamm. Genome 12: 930-932.
25. Bernal, A., T. Proft, J. D. Fraser, and D. N. Posnett. 1999. Superantigens in human disease. J. Clin. Immunol. 19: 149-157.
26. Papageorgiou, A. C., and K. R. Acharya. 2000. Microbial superantigens: from structure to function. Trends Microbiol. 8: 369-375.
27. Herman, A., J. W. Kappler, P. Marrack, and A. M. Pullen. 1991. Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol. 9: 745-772.
28. Kappler, J., B. Kotzin, L. Herron, E. W. Gelfand, R. D. Bigler, A. Boylston, S. Carrel, D. N. Posnett, Y. Choi, and P. Marrack. 1989. Vβ-specific stimulation of human T cells by staphylococcal toxins. Science 244: 811-813.
29. Van Amersfoort, E. S., T. J. Van Berkel, and J. Kuiper. 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev. 16: 379-414.
30. Keller, R., W. Fischer, R. Keist, and S. Bassetti. 1992. Macrophage response to bacteria: induction of marked secretory and cellular activities by lipoteichoic acids. Infect. Immun. 60: 3664-3672.
31. De Kimpe, S. J., M. Kengatharan, C. Thiemermann, and J. R. Vane. 1995. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl. Acad. Sci. USA 92: 10359-10363.
32. Cleveland, M. G., J. D. Gorham, T. L. Murphy, E. Tuomanen, and K. M. Murphy. 1996. Lipoteichoic acid preparations of Gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect. Immun. 64: 1906-1912.
33. Ginsburg, I. 2002. Role of lipoteichoic acid in infection and inflammation. Lancet Infect. Dis. 2: 171-179.
34. Gupta, D., T. N. Kirkland, S. Viriyakosol, and R. Dziarski. 1996. CD14 is a cell-activating receptor for bacterial peptidoglycan. J. Biol. Chem. 271: 23310-23316.
35. Hack, C. E., L. A. Aarden, and L. G. Thijs. 1997. Role of cytokines in sepsis. Adv. Immunol. 66: 101-195.
36. Dinarello, C. A. 1997. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112: 321S-329S.
37. Hack, C. E., E. R. De Groot, R. J. Felt-Bersma, J. H. Nuijens, R. J. Strack Van Schijndel, A. J. Eerenberg-Belmer, L. G. Thijs, and L. A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704-1710.
38. Gennari, R., and J. W. Alexander. 1995. Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Crit. Care Med. 23: 1945-1953.
39. Spittler, A., M. Razenberger, H. Kupper, M. Kaul, W. Hackl, G. Boltz-Nitulescu, R. Fugger, and E. Roth. 2000. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin. Infect. Dis. 31: 1338-1342.
40. Riedemann, N. C., T. A. Neff, R. F. Guo, K. D. Bernacki, I. J. Laudes, I. V. Sarma, J. D. Lambris, and P. A. Ward. 2003. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170: 503-507.
41. Damas, P., D. LeDoux, M. Nijs, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum levels during severe sepsis in humans: IL-6 as a marker of severity. Ann. Surg. 215: 356-362.
42. Norrby-Teglund, A., K. Pauksens, M. Norgren, and S. E. Holm. 1995. Correlation between serum TNFα and IL-6 levels and severity of group A streptococcal infections. Scand. J. Infect. Dis. 27: 125-130.
43. Munoz, C., J. Carlet, C. Fitting, B. Misset, J. P. Bleriot, and J. M. Cavaillon. 1991. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88: 1747-1754.
44. Gruen, J. R., and S. M. Weissman. 1997. Evolving views of the major histocompatibility complex. Blood 90: 4252-4265.
45. Aderka, D., J. M. Le, and J. Vilcek. 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143: 3517-3523.
46. Di Santo, E., T. Alonzi, V. Poli, E. Fattori, C. Toniatti, M. Sironi, P. Ricciardi-Castagnoli, and P. Ghezzi. 1997. Differential effects of IL-6 on systemic and central production of TNF: a study with IL-6-deficient mice. Cytokine 9: 300-306.
47. Bethin, K. E., S. K. Vogt, and L. J. Muglia. 2000. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc. Natl. Acad. Sci. USA 97: 9317-9322.
48. Papasian, C. J., R. Silverstein, J. J. Gao, D. M. Bamberger, and D. C. Morrison. 2002. Anomalous role of tumor necrosis factor α in experimental enterococcal infection. Infect. Immun. 70: 6628-6637.
49. Akira, S., and T. Kishimoto. 1996. Role of interleukin-6 in macrophage function. Curr. Opin. Hematol. 3: 87-93.
50. Van Molle, W., B. Wielockx, T. Mahieu, M. Takada, T. Taniguchi, K. Sekikawa, and C. Libert. 2002. HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 16: 685-695.
51. Kiang, J. G., and G. C. Tsokos. 1998. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol. Ther. 80: 183-201.
52. Asea, A., S. K. Kraeft, E. A. Kurt-Jones, M. A. Stevenson, L. B. Chen, R. W. Finberg, G. C. Koo, and S. K. Calderwood. 2000. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6: 435-442.
53. Housby, J. N., C. M. Cahill, B. Chu, R. Prevelige, K. Bickford, M. A. Stevenson, and S. K. Calderwood. 1999. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine 11: 347-358.
54. Nishimura, H., M. Emoto, K. Kimura, and Y. Yoshikai. 1997. Hsp70 protects macrophages infected with Salmonella choleraesuis against TNF-α-induced cell death. Cell Stress Chaperones 2: 50-59.
55. Ribeiro, S. P., J. Villar, G. P. Downey, J. D. Edelson, and A. S. Slutsky. 1996. Effects of the stress response in septic rats and LPS-stimulated alveolar macrophages: evidence for TNF-α posttranslational regulation. Am. J. Respir. Crit. Care Med. 154: 1843-1850.
56. Temple, S. E., K. Y. Cheong, K. G. Ardlie, D. Sayer, and G. W. Waterer. 2004. The septic shock associated HSPA1B1267 polymorphism influences production of HSPA1A and HSPA1B. Intensive Care Med. 30: 1761-1767.
57. Waterer, G. W., L. ElBahlawan, M. W. Quasney, Q. Zhang, L. A. Kessler, and R. G. Wunderink. 2003. Heat shock protein 70-2 + 1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit. Care Med. 31: 1367-1372.
58. Kelley, J., L. Walter, and J. Trowsdale. 2005. Comparative genomics of major histocompatibility complexes. Immunogenetics 56: 683-695.